Sareum Holdings Plc - Product Pipeline Review - 2015

Date: December 9, 2015
Pages: 40
Price:
US$ 1,500.00 US$ 1,275.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S17D2778389EN
Leaflet:

Download PDF Leaflet

Sareum Holdings Plc - Product Pipeline Review - 2015

SUMMARY

Global Markets Direct’s, ‘Sareum Holdings plc - Product Pipeline Review - 2015’, provides an overview of the Sareum Holdings plc’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sareum Holdings plc’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides brief overview of Sareum Holdings plc including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Sareum Holdings plc’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Sareum Holdings plc’s pipeline products
REASONS TO BUY
  • Evaluate Sareum Holdings plc’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Sareum Holdings plc in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Sareum Holdings plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Sareum Holdings plc and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sareum Holdings plc
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Sareum Holdings plc and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Sareum Holdings Plc Snapshot
Sareum Holdings Plc Overview
Key Information
Key Facts
Sareum Holdings Plc - Research and Development Overview
Key Therapeutic Areas
Sareum Holdings Plc - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Sareum Holdings Plc - Pipeline Products Glance
Sareum Holdings Plc - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Sareum Holdings Plc - Drug Profiles
CCT-244747
Product Description
Mechanism of Action
R&D Progress
CCT-245737
Product Description
Mechanism of Action
R&D Progress
SAR-020106
Product Description
Mechanism of Action
R&D Progress
SAR-20347
Product Description
Mechanism of Action
R&D Progress
SAR-3
Product Description
Mechanism of Action
R&D Progress
SAR-4
Product Description
Mechanism of Action
R&D Progress
SART-1
Product Description
Mechanism of Action
R&D Progress
SART-29
Product Description
Mechanism of Action
R&D Progress
SART-33
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize VEGFR-3 for Oncology
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit B-RAF Kinase for Oncology
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Polo-Like Kinase-1 for Oncology
Product Description
Mechanism of Action
R&D Progress
Sareum Holdings Plc - Pipeline Analysis
Sareum Holdings Plc - Pipeline Products by Target
Sareum Holdings Plc - Pipeline Products by Route of Administration
Sareum Holdings Plc - Pipeline Products by Molecule Type
Sareum Holdings Plc - Pipeline Products by Mechanism of Action
Sareum Holdings Plc - Recent Pipeline Updates
Sareum Holdings Plc - Dormant Projects
Sareum Holdings Plc - Company Statement
Sareum Holdings Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Sareum Holdings Plc, Key Information
Sareum Holdings Plc, Key Facts
Sareum Holdings Plc - Pipeline by Indication, 2015
Sareum Holdings Plc - Pipeline by Stage of Development, 2015
Sareum Holdings Plc - Monotherapy Products in Pipeline, 2015
Sareum Holdings Plc - Preclinical, 2015
Sareum Holdings Plc - Discovery, 2015
Sareum Holdings Plc - Pipeline by Target, 2015
Sareum Holdings Plc - Pipeline by Route of Administration, 2015
Sareum Holdings Plc - Pipeline by Molecule Type, 2015
Sareum Holdings Plc - Pipeline Products by Mechanism of Action, 2015
Sareum Holdings Plc - Recent Pipeline Updates, 2015
Sareum Holdings Plc - Dormant Developmental Projects,2015
Sareum Holdings Plc, Subsidiaries

LIST OF FIGURES

Sareum Holdings Plc - Pipeline by Top 10 Indication, 2015
Sareum Holdings Plc - Pipeline by Stage of Development, 2015
Sareum Holdings Plc - Monotherapy Products in Pipeline, 2015
Sareum Holdings Plc - Pipeline by Top 10 Target, 2015
Sareum Holdings Plc - Pipeline by Top 10 Route of Administration, 2015
Sareum Holdings Plc - Pipeline by Top 10 Molecule Type, 2015
Sareum Holdings Plc - Pipeline Products by Top 10 Mechanism of Action, 2015
Skip to top


Scancell Holdings Plc - Product Pipeline Review - 2015 US$ 1,275.00 Nov, 2015 · 26 pages
Epistem Holdings Plc - Product Pipeline Review - 2015 US$ 1,275.00 Dec, 2015 · 23 pages
e-Therapeutics Plc - Product Pipeline Review - 2015 US$ 1,200.00 Jul, 2015 · 34 pages
Amura Holdings Ltd. - Product Pipeline Review - 2015 US$ 1,200.00 Apr, 2015 · 22 pages
Vaxeal Holding SA - Product Pipeline Review - 2015 US$ 1,275.00 Dec, 2015 · 18 pages

Ask Your Question

Sareum Holdings Plc - Product Pipeline Review - 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: